Take­da fore­casts $1.7B loss af­ter Shire in­te­gra­tion; Flag­ship's pre­clin­i­cal biotech Ax­cel­la clos­es IPO with $71M+ haul

→ Take­da’s $TAK first set of fi­nan­cial re­sults since con­sum­mat­ing its $62 bil­lion ac­qui­si­tion of Shire is in, and it’s giv­ing an­a­lysts a neg­a­tive sur­prise. Cit­ing costs for in­te­grat­ing the Ire­land-based Shire, the Japan­ese drug­mak­er fore­casts an op­er­at­ing loss of $1.7 bil­lion (193 bil­lion yen) for the year through March 2019 — where an­a­lysts sur­veyed by Re­fini­tiv es­ti­mat­ed a prof­it of $2.08 bil­lion (227.5 bil­lion yen), ac­cord­ing to Reuters. The pre­dic­tions come as Take­da at­tempts to re­lieve its mas­sive debt bur­den by di­vest­ing its non-core as­sets, in­clud­ing a dry eye drug and a sur­gi­cal patch sold to No­var­tis and J&J last week, re­spec­tive­ly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER